2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative
Jazyk angličtina Země Anglie, Velká Británie Médium print
Typ dokumentu konsensus - konference, časopisecké články, směrnice pro lékařskou praxi, validační studie
Grantová podpora
MR/P020941/1
Medical Research Council - United Kingdom
ZIA ES101081-15
Intramural NIH HHS - United States
ZIA ES101081-14
Intramural NIH HHS - United States
ZIA ES101081-13
Intramural NIH HHS - United States
MR/K006312/1
Medical Research Council - United Kingdom
MR/N003322/1
Medical Research Council - United Kingdom
ZIA ES101081-12
Intramural NIH HHS - United States
Z99 ES999999
Intramural NIH HHS - United States
PubMed
28385805
PubMed Central
PMC5496443
DOI
10.1136/annrheumdis-2017-211400
PII: S0003-4967(24)02782-1
Knihovny.cz E-zdroje
- Klíčová slova
- Dermatomyositis, Polymyositis, Treatment,
- MeSH
- dermatomyozitida terapie MeSH
- dítě MeSH
- dospělí MeSH
- hodnocení výsledků zdravotní péče normy MeSH
- konsensus MeSH
- lidé MeSH
- mladiství MeSH
- polymyozitida terapie MeSH
- předškolní dítě MeSH
- randomizované kontrolované studie jako téma MeSH
- senzitivita a specificita MeSH
- stupeň závažnosti nemoci * MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- předškolní dítě MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- směrnice pro lékařskou praxi MeSH
- validační studie MeSH
To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
Academic Medical Center Amsterdam The Netherlands
Brigham and Women's Hospital and Harvard Medical School Boston Massachusetts USA
Central Manchester University Hospitals NHS Foundation Trust University of Manchester Manchester UK
Charles University Prague Czech Republic
Istituto Giannina Gaslini Pediatria 2 Rheumatologia PRINTO Genoa Italy
Johns Hopkins University School of Medicine Baltimore Maryland USA
Karolinska University Hospital Karolinska Institute Stockholm Sweden
Mayo Clinic Rochester Minnesota USA
NIEHS NIH Bethesda Maryland USA
Social and Scientific Systems Inc Durham North Carolina USA
Stanford University Redwood City California USA
The Hospital for Sick Children Toronto Ontario Canada
University College London London UK
University of Debrecen Debrecen Hungary
Zobrazit více v PubMed
Rider LG, Miller FW. Deciphering the clinical presentations, pathogenesis, and treatment of the idiopathic inflammatory myopathies. JAMA. 2011;305(2):183–90. PubMed PMC
Moghadam-Kia S, Aggarwal R, Oddis CV. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol. 2015;11(11):1265–75. PubMed PMC
Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24. PubMed PMC
Muscle Study Group. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70(3):427–36. PubMed PMC
Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8. PubMed
Rider LG, Werth VP, Huber AM, Alexanderson H, Rao AP, Ruperto N, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), Physician Global Damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI) Arthritis Care Res (Hoboken ) 2011;63(Suppl 11):S118–S157. PubMed PMC
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001;40(11):1262–73. PubMed
Rider LG, Giannini EH, Harris-Love M, Joe G, Isenberg D, Pilkington C, et al. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol. 2003;30(3):603–17. PubMed
Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50(7):2281–90. PubMed
American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193–202. PubMed
de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, et al. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds(R) Consensus Exercises. Arthritis Care Res (Hoboken ) 2016;68(5):667–72. PubMed
Johnson SR, Naden RP, Fransen J, Van Den Hoogen F, Pope JE, Baron M, et al. Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. J Clin Epidemiol. 2014;67(6):706–14. PubMed PMC
Hansen P, Ombler F. A new method for scoring additive multi-attribute value models using pairwise rankings of alternatives. J Multi-Crit Decis Anal. 2008;15:87–107.
Amaya-Amaya M, Gerard K, Ryan M. Discrete choice experiments in a nutshell. In: Ryan M, Gerard K, Amaya-Amaya M, editors. Using Discrete Choice Experiments to Value Health and Health Care. Dordrecht: Springer; 2008.
Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO) Arch Dis Child. 2011;96(6):596–601. PubMed
Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, et al. Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials. J Rheumatol. 2011;38(7):1467–70. PubMed
Taylor WJ, Brown M, Aati O, Weatherall M, Dalbeth N. Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria? Arthritis Care Res (Hoboken) 2013;65(8):1259–64. PubMed
Utz KS, Hoog J, Wentrup A, Berg S, Lammer A, Jainsch B, et al. Patient preferences for disease-modifying drugs in multiple sclerosis therapy: a choice-based conjoint analysis. Ther Adv Neurol Disord. 2014;7(6):263–75. PubMed PMC
de Bekker-Grob E, Ryan M, Gerard K. Discrete choice experiments in health economics: a review of the literature. Health Econ. 2012;21:145–72. PubMed
Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, et al. 2016 American College of Rheumatology (ACR) - European League Against Rheumatism (EULAR) Criteria for Minimal, Moderate and Major Clinical Response for Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2016;00(00):000. PubMed
Rider LG. Outcome assessment in the adult and juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 2002;28(4):935–77. PubMed
Aggarwal R, Rider LG, Ruperto N, Bayat N, Erman B, Feldman BM, et al. A consensus hybrid definition using a conjoint analysis is the proposed response criteria for minimal and moderate improvement for adult polymyositis and dermatomyositis clinical trials. Arthritis Rheumatol. 2014;66(S11):S404.
Rider LG, Ruperto N, Pistorio A, Erman B, Bayat N, Lachenbruch PA, et al. Development of Adult Dermatomyositis and Polymyositis and Juvenile Dermatomyositis Response Criteria--Methodological Aspects: An American College of Rheumatology/European League Against Rheumatism/International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Rheumatology (Oxford) 2016;2016 Submitted. PubMed
Bohan A, Peter JB. Polymyositis and dermatomyositis. Parts 1 and 2. N Engl J Med. 1975;292:344–7. 3403–407. PubMed
Rider LG, Lee J, Jansen A, Ruperto N, Huber AM, Oddis CV, et al. Defining clinically relevant changes in core set activity measures for adult and juvenile idiopathic inflammatory myopathies (IIM) Arthritis Rheum. 2011;63(Suppl):S89.
Metz CE. Basic principles of ROC analysis. Semin Nucl Med. 1978;8(4):283–98. PubMed
Ruperto N, Meiorin S, Iusan SM, Ravelli A, Pistorio A, Martini A. Consensus procedures and their role in pediatric rheumatology. Curr Rheumatol Rep. 2008;10(2):142–6. PubMed
Delbecq A, Van de Ven A, Gustafson D. A guide to nominal group and delphi processes. Glenview, IL: Scott, Foresman and Company; 1975. Group techniques for program planning.
Nair R, Aggarwal R, Khanna D. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum. 2011;41(2):95–105. PubMed PMC
Ruperto N, Ozen S, Pistorio A, Dolezalova P, Brogan P, Cabral DA, et al. EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. Ann Rheum Dis. 2010;69(5):790–7. PubMed
Piram M, Kone-Paut I, Lachmann HJ, Frenkel J, Ozen S, Kuemmerle-Deschner J, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168–73. PubMed PMC
Ruperto N, Ravelli A, Pistorio A, Ferriani V, Calvo I, Ganser G, et al. The provisional Paediatric Rheumatology International Trials Organisation/American College of Rheumatology/European League Against Rheumatism Disease activity core set for the evaluation of response to therapy in juvenile dermatomyositis: a prospective validation study. Arthritis Rheum. 2008;59(1):4–13. PubMed
Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin Exp Rheumatol. 2001;19(Suppl 23):S1–S9. PubMed
Apaz MT, Saad-Magalhaes C, Pistorio A, Ravelli A, de Oliveira SJ, Marcantoni MB, et al. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. Arthritis Rheum. 2009;61(4):509–17. PubMed
Van Den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737–47. PubMed PMC
Neogi T, Aletaha D, Silman AJ, Naden RL, Felson DT, Aggarwal R, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum. 2010;62(9):2582–91. PubMed PMC
Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557–68. PubMed PMC
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35. PubMed
Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63(3):573–86. PubMed PMC
Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73(1):227–32. PubMed PMC
Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis. 2006;65(12):1635–8. PubMed PMC
Tjarnlund A, Bottai M, Rider LG, Werth VP, Pilkington C, de Visser M, et al. Progress report on development of classification criteria for adult and juvenile idiopathic inflammatory myopathies. Arthritis & Rheumatism. 2012;64(Suppl):S323–S324.
Alexanderson H, Del GM, Bingham CO, III, Orbai AM, Sarver C, Clegg-Smith K, et al. Patient-reported outcomes and adult patients’ disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group. J Rheumatol. 2014;41(3):581–92. PubMed PMC
Volochayev R, Csako G, Wesley R, Rider LG, Miller FW. Laboratory Test Abnormalities are Common in Polymyositis and Dermatomyositis and Differ Among Clinical and Demographic Groups. Open Rheumatol J. 2012;6:54–63. PubMed PMC
Idiopathic inflammatory myopathies
Opportunities and challenges in rheumatology research in Central Europe